Iovance Biotherapeutics Investor Presentation — March 2019

Document content

Beyond Machines for Antigen Selection:

Using ATLAS™ to Enable Novel Cancer Immunotherapies

M a r c h 2 0 1 92

This presentation contains “forward -looking” statements that are within the meaning of federal securities laws and are based on our management’s

beliefs and assumptions and on information currently available to management. Forward -looking statements include information con cerning our

possible or assumed future results of operations, business strategies, clinical trials and pre -clinical studies, regulatory appr oval of our product

candidates, liquidity position and capital needs, financing plans, industry environment, potential growth opportunities, pote ntial market opportunities

and the effects of competition.

Forward -looking statements include all statements that are not historical facts and can be identified by terms such as “anticipa tes,” “believes,”

“expects,” “could,” “seeks,” “estimates,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “ wou ld” or similar expressions

and the negatives of those terms. Forward -looking statements represent our management’s beliefs and assumptions only as of the d ate of this

presentation. Our operations involve risks and uncertainties, many of which are outside our control, and any one of which, or combination of which,

could materially affect our results of operations and whether the forward -looking statements ultimately prove to be correct. Fa ctors that may

materially affect our results of operations include, among other things, our ability to progress product candidates in precli nical and clinical trials, the

ability of ATLAS™to identify promising oncology vaccine and immunotherapy product candidates, the scope, rate and progress of our preclinical and

clinical trials and other research and development activities, anticipated timing of new clinical trails, our estimates regar ding the amount of funds we

require to conduct our clinical trials for GEN -009, our plans to commercialize GEN -009, the timing of, and ability to, obtain an d maintain necessary

regulatory approvals for our product candidates, and those listed in our Annual Report on Form 10 -K for the fiscal year ended De cember 31, 2017 and

other filings with the Securities and Exchange Commission (“SEC”). Except as required by law, we assume no obligation to upda te these forward -looking

statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward -looki ng statements, even if

new information becomes available in the future.

You may get copies of our Annual Report on Form 10 -K, Quarterly Report on Form 10 -Q and our other SEC filings for free by visiti ng EDGAR on the SEC